Clinical Analgesic Management in Dementia (CALM-D)

Capital Medical University

Status and phase

Enrolling

Phase 3

Conditions

Alzheimer Disease

Treatments

Drug: Tylex

Study type

Interventional

Funder types

Other

Identifiers

NCT07323914

2025005001

Details and patient eligibility

About

This study is designed to assess the efficacy and safety of oxycodone in managing moderate to severe pain in patients with Alzheimer's disease. The trial will be conducted at Xuanwu Hospital, Capital Medical University, and will enroll 10 eligible participants. Participants will receive oxycodone/acetaminophen (5 mg/325 mg) once daily for 12 weeks. The treatment will follow international guidelines, with dosages adjusted based on the patient's baseline pain levels and individual needs. Dosages will be adjusted based on baseline pain levels and patient needs, following international guidelines. Efficacy and adverse events will be assessed at baseline, week 6, week 12, and at a 12-week post-treatment follow-up. The primary outcome is change in VAS pain scores; secondary outcomes include PAINAD, SF-36, functional ability, and safety profiles.

Enrollment

10 estimated patients

Sex

All

Ages

50 to 90 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Male or female, aged 50 to 90 years at the time of enrollment.
Meets the NIA-AA core clinical diagnostic criteria for probable Alzheimer's disease.
Clinical Dementia Rating - Global Score (CDR-GS) between 0.5 and 2.0, inclusive, and Clinical Dementia Rating - Memory Box (CDR-MB) score ≥ 0.5.
Diagnosed with chronic pain within 6 months prior to enrollment and considered appropriate for opioid therapy.
Presence and severity of pain confirmed using PAINAD, MOBID-2, or comparable scales.
Educational attainment: at least 4-6 years of formal education, or not illiterate.
If currently receiving psychotropic or cognitive-enhancing medications, the dosage must have been stable for at least 3 months prior to study entry and remain unchanged during the study. Unless otherwise specified, all other permitted concomitant medications (non-AD related) must be stably administered for at least 4 weeks prior to baseline.
Has a reliable caregiver/companion who can assist with study participation, defined as a person who can support the participant throughout the study and spend at least 8 hours per week with the participant.
Willing and able to participate in this clinical trial, to maintain the assigned intervention during the study period, and has signed the informed consent form.

Exclusion criteria

History of transient ischemic attack (TIA), stroke, or seizure within the past 12 months.
Presence of any psychiatric diagnosis or symptoms that may interfere with study participation (e.g., hallucinations, major depression, or delusions).
Known allergy to opioid analgesics.
Severe visual or hearing impairment.
Alcohol dependence, substance abuse, or other drug addiction or addictive tendency.
Current participation in another study related to the treatment of Alzheimer's disease.
Any other uncontrolled or inadequately treated medical condition (e.g., cardiac, respiratory, gastrointestinal, hepatic, or renal disease), or any condition judged by the investigator to compromise participant safety or interfere with study assessments.
Any other reason deemed by the investigator to preclude participation in the study.